Vistagen reports fiscal year 2025 financial results and provides corporate update

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended march 31, 2025, and provided a corporate update. “this was a defining year for vistagen, marked by significant progress in our registration-directed palisade program for fa.
VTGN Ratings Summary
VTGN Quant Ranking